GLP-1 Safety Newsroom
FDA Alerts, Recalls & Provider Safety Data
We aggregate publicly available FDA enforcement data, warning letters, and regulatory actions so you can make informed decisions about GLP-1 providers and compounding pharmacies.
Latest FDA Actions
View all →FDA Issues Warning Letters to 7 Companies Marketing Unapproved GLP-1 Products
The FDA sent warning letters to seven companies for selling products marketed as GLP-1 receptor agonists that were not approved, cleared, or authorized by the FDA.
FDA Announces Intent to Restrict Ingredients in Mass-Marketed Compounded GLP-1 Drugs
The FDA announced plans to limit certain ingredients used in compounded GLP-1 medications that are marketed on a large scale, signaling tighter regulation of the compounding industry.
FDA Issues 30 Warning Letters to GLP-1 Telehealth Companies for Misleading Marketing
The FDA sent warning letters to 30 telehealth companies for making false or misleading marketing claims about compounded GLP-1 medications, including claims of equivalence to FDA-approved products.
FDA Officially Resolves Semaglutide Injection Shortage
The FDA announced that the semaglutide injection shortage has been officially resolved, which changes the legal basis for some compounding of semaglutide products.
FDA Updates Safety Communication on Compounded GLP-1 Drugs for Weight Loss
The FDA updated its safety communication highlighting concerns about unapproved compounded GLP-1 drugs used for weight loss, citing over 1,100 adverse event reports.
Companies With FDA Warning Letters
GLP-1 Safety Alerts
Get notified when the FDA issues warning letters, recalls, or regulatory updates affecting GLP-1 medications and compounding pharmacies.
Free. No spam. Unsubscribe anytime.
All Tracked Companies
View all →Alpha Medical
TelehealthMulti-service telehealth platform offering GLP-1 prescribing for weight management alongside women's health, dermatology, mental health, and primary care.
Alpha Medical is a multi-condition telehealth brand rather than a dedicated GLP-1 clinic.
Belmar Pharmacy
503A PharmacyColorado-based 503A compounding pharmacy focused on patient-specific prescriptions across hormone therapy, peptides, and weight-management compounds including GLP-1 formulations.
Belmar is a patient-specific compounding pharmacy rather than a mass-market telehealth platform.
Calibrate
TelehealthMetabolic health company offering structured GLP-1 programs with physician oversight, baseline assessments, and long-term behavior-change support.
Calibrate is positioned as a programmatic metabolic-health offering, not just a GLP-1 storefront.
Done
TelehealthOnline healthcare platform expanding beyond its earlier ADHD focus into GLP-1 weight-loss treatment and other telehealth services.
Done is a broader telehealth platform rather than a pure-play GLP-1 brand.
Empower Pharmacy
503A PharmacyLarge FDA-registered 503B outsourcing facility and compounder with a major national footprint in sterile and non-sterile medication production, including GLP-1-related products.
Empower is frequently relevant because it may be the actual compounding or outsourcing facility behind a telehealth prescription flow.
Found
TelehealthTelehealth weight-loss platform combining GLP-1 access with coaching, nutrition support, and a broader behavior-change framework.
Found combines medication access with coaching and habit-change support.
Hallandale Pharmacy
503A PharmacyFlorida-based compounder operating across 503B outsourcing and 503A pharmacy functions, with a significant presence in sterile medication fulfillment.
Hallandale matters because it may sit behind the scenes of telehealth GLP-1 fulfillment rather than in front of the patient.
Henry Meds
TelehealthTelehealth company centered on compounded GLP-1 weight loss access through online consultations and subscription-style recurring billing.
Henry Meds is usually compared against other lower-cost compounded GLP-1 telehealth providers rather than premium obesity-medicine programs.
What We Track
Warning Letters
FDA warning letters to GLP-1 telehealth companies and compounding pharmacies for false or misleading claims.
Recalls
Drug recalls and enforcement actions from the openFDA database, updated weekly.
Shortage Updates
Drug shortage status changes for semaglutide, tirzepatide, and compounded formulations.
Regulatory Changes
Policy updates from FDA, HHS, and state pharmacy boards affecting compounded GLP-1 medications.
Frequently Asked Questions
What is the FormBlends Safety Newsroom?
The Safety Newsroom aggregates publicly available FDA data including warning letters, drug recalls, shortage updates, and regulatory changes affecting GLP-1 medications and compounding pharmacies. All data comes from government sources like the openFDA API and FDA.gov.
How often is safety data updated?
We poll the openFDA enforcement database twice weekly (Monday and Thursday). Warning letters and regulatory changes are added as they are published by the FDA. Entity profiles are verified at least monthly.
Does a clean safety record mean a company is safe?
Not necessarily. The absence of FDA warning letters or recalls does not guarantee product safety or quality. Our data reflects publicly available government records, which may not capture all relevant information. Always consult your healthcare provider.
Can I look up any pharmacy or telehealth company?
You can search our database using the Pharmacy Lookup tool. We currently track the major GLP-1 telehealth providers and compounding pharmacies. If a company isn't in our database, you can request we add it.
What is the difference between a 503A and 503B pharmacy?
503B outsourcing facilities are registered with and inspected by the FDA, and must follow current good manufacturing practices (cGMP). 503A compounding pharmacies are primarily regulated by state pharmacy boards and compound based on individual patient prescriptions.
Safety Guides
503A vs 503B pharmacies
The critical difference in FDA oversight and what it means for your medication.
How to read a Certificate of Analysis
What to look for on your CoA and red flags that indicate quality problems.
Red flags in peptide vendors
Warning signs that a vendor may not be legitimate or safe.
What FDA registration actually means
Registration vs approval: the distinction most consumers get wrong.
Compounding pharmacy regulations
Federal and state rules governing how your medication gets made.
How to report adverse reactions
Step-by-step guide to filing an FDA MedWatch report.
About this data: All information on this page comes from publicly available government sources including the FDA, openFDA API, and state pharmacy board records. This is not a rating or endorsement system. The presence or absence of a company in our database does not indicate safety, quality, or legitimacy. Always verify information with official sources and consult your healthcare provider.